Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Identifying the mechanism of adverse inflammatory events induced by red blood cell antibody therapy in immune thrombocytopenia

FY 2020-21

Summary
Immune thrombocytopenia (ITP) is the most common bleeding disorder in children and the case number is continuously rising. This disease is characterized by an abnormally low level of platelets, a cell type that prevents blood loss by forming clots. Thus, patients experience symptoms of easy or excessive bleeding. Currently, the treatment for a significant proportion of patients is either IVIg or anti-D, both of which are specific proteins isolated from blood donations. Unfortunately, these medications have considerable side effects, notably severe inflammation throughout the body. Our lab possesses molecules, called RBC antibodies, that are very similar to anti-D in function. These show therapeutic effects in a mouse model of ITP, but likewise cause inflammation. Understanding how RBC antibodies induce inflammation is a crucial step in uncovering potential ways to prevent it. In the human body, inflammation is caused in various ways, but researchers have identified a relationship between thrombocytopenia and a specific protein involved in inflammation, known as PAF. Interestingly, our lab also discovered that PAF and RBC antibodies stimulate the immune system in similar manners. Therefore, we theorize that PAF is the key protein causing the inflammation associated with RBC antibodies. We will study this by analyzing changes in PAF levels in mice that have been given RBC antibodies. In addition, there are compounds that block the activity of PAF. Thus, our subsequent focus will be to examine whether these inflammatory effects can be reduced or avoided by blocking PAF activity. By providing insight into how these therapies cause inflammation, we can work towards preventing it, and ultimately deliver a safer treatment option to patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449762
Name
Won Doyoon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying the mechanism of adverse inflammatory events induced by red blood cell antibody therapy in immune thrombocytopenia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-D; Antibody Therapy; Autoimmunity; Immune Thrombocytopenia; Immunopathology; Inflammation; Intravenous Immunoglobulin; Platelet-Activating Factor; Platelets; Red Blood Cells
Abstract
Immune thrombocytopenia (ITP) is the most common bleeding disorder in children and the case number is continuously rising. This disease is characterized by an abnormally low level of platelets, a cell type that prevents blood loss by forming clots. Thus, patients experience symptoms of easy or excessive bleeding. Currently, the treatment for a significant proportion of patients is either IVIg or anti-D, both of which are specific proteins isolated from blood donations. Unfortunately, these medications have considerable side effects, notably severe inflammation throughout the body. Our lab possesses molecules, called RBC antibodies, that are very similar to anti-D in function. These show therapeutic effects in a mouse model of ITP, but likewise cause inflammation. Understanding how RBC antibodies induce inflammation is a crucial step in uncovering potential ways to prevent it. In the human body, inflammation is caused in various ways, but researchers have identified a relationship between thrombocytopenia and a specific protein involved in inflammation, known as PAF. Interestingly, our lab also discovered that PAF and RBC antibodies stimulate the immune system in similar manners. Therefore, we theorize that PAF is the key protein causing the inflammation associated with RBC antibodies. We will study this by analyzing changes in PAF levels in mice that have been given RBC antibodies. In addition, there are compounds that block the activity of PAF. Thus, our subsequent focus will be to examine whether these inflammatory effects can be reduced or avoided by blocking PAF activity. By providing insight into how these therapies cause inflammation, we can work towards preventing it, and ultimately deliver a safer treatment option to patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Won, Doyoon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~